media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Lenvatinib Mesylate Capsules Receive Drug Registration Certificate

On August 7th, Lu Kang Pharmaceutical(600789) announced that it has obtained a Drug Registration Certificate for Lenvatinib Mesylate Capsules from the National Medical Products Administration. This approval supports the enrichment of the company’s pharmaceutical product pipeline. Lenvatinib mesylate is a tyrosine kinase receptor inhibitor indicated for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy. Its domestic sales in 2025 and the first quarter of 2026 were RMB 649 million and RMB 419 million, respectively. The company’s R&D investment in this drug was approximately RMB 8.59 million (unaudited). In the first quarter of 2026, Lu Kang Pharmaceutical achieved revenue of 1.616 billion yuan and net profit attributable to the parent company of 53.25 million yuan. https://finance.eastmoney.com/a/202608073835349687.html
- Source: drugdu
- 139
- August 13, 2026
Subsidiary’s self-developed Class 1 innovative drug, bemosubalimab injection, in combination therapy, has been approved for marketing.

　　On August 7, China Biopharmaceutical (01177) issued an announcement stating that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has independently developed a Class 1 innovative drug.Bemosubalimab injection in combination with chemotherapy followed by anlotinib hydrochloride capsules has been approved for marketing by the National Medical Products Administration of China for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer. 　　The announcement mentioned that this is the 12th approved indication for anlotinib and the 6th approved indication for bemosubib. https://finance.eastmoney.com/a/202608073835411830.html
- Source: drugdu
- 67
- August 13, 2026
Hanyu Pharmaceutical has licensed 3SBio’s Smegglutide injection to commercialize the product, with sales milestones reaching up to 145 million yuan.

On August 12, Hanyu Pharmaceutical(300199) issued an announcement stating that the company has reached an agreement with Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd., and the two parties have reached a cooperation agreement on the development, registration, production and commercialization of Smegglutide injection (for blood glucose control) in China (excluding Taiwan). The company granted 3SBio an exclusive, non-transferable, and sublicensable license in the region, under which 3SBio or its affiliates shall act as the marketing authorization holder for the collaborative products in China and be solely responsible for the commercialization of the collaborative products in the region. The financial terms of this collaboration consist of three parts: an initial payment to 3SBio for signing the agreement, milestone payments for registration and commercialization, and sales royalties. The initial payment is RMB 12 million. The milestone payments for registration and commercialization include RMB 18 million upon approval of the blood glucose indication for ...
- Source: drugdu
- 68
- August 13, 2026
Shenyang Medical Exhibition

Organiser： Shenyang Medical Exhibition Organizing Committee Time：August 20, 2026 – August 22, 2026 Address：No. 9 Huizhan Road, Sujiatun District, Shenyang Exhibition hall：Shenyang International Exhibition Center Product range: Medical Imaging‌: CT, DR radiology equipment, ultrasound imaging equipment, medical X-ray equipment, magnetic resonance equipment, nuclear medicine equipment, medical optical equipment, medical films and interventional products, etc. ‌Medical Electronics‌: Functional examination equipment, endoscopic examination equipment, pathological diagnosis equipment, cardio-encephalomyography diagnostic equipment, monitoring instruments, respiratory equipment, anesthesia and analgesia equipment, laser equipment, cryogenic freezing equipment, first-aid equipment, etc. ‌In-Vitro Diagnostics and Laboratory Medicine‌: Clinical diagnostic equipment, diagnostic reagents, biochemical testing equipment, POCT, overall laboratory solutions, biochemical analysis instruments, chromatographic analyzers, clinic analyzers, home diagnostic equipment, etc. ‌Operating Room Equipment and Surgical Instruments‌: Integrated operating rooms, anesthesia machines, ventilators, monitors, operating tables, shadowless lamps, pendant towers, surgical instruments, electrosurgical units and consumables, staplers, suturing devices, suture needles/threads, laser surgical instruments, ultrasound surgery, surgical engineering, ...
- Source: drugdu
- 72
- August 13, 2026
Miraberon API Receives FDA Registration Approval

China Securities Intelligent Finance – Tonghe Pharmaceutical(300636) announced on the evening of August 11 that the company recently received Miraberon API issued by the U.S. Food and Drug Administration.The NFC Letter indicates that the FDA has completed its technical review of the company’s DMF file for the Miraberon active pharmaceutical ingredient , which meets the ANDA application requirements of related formulation customers. The announcement indicates that mirabezone is a selective β3-adrenergic receptor agonist that can improve bladder filling and storage capacity by activating β3-adrenergic receptors on the bladder detrusor muscle. Clinically, it is used to treat overactive bladder with symptoms such as urge incontinence, urgency, and frequency. The company stated that the successful technical review of Mirabelon API will facilitate market expansion and customer acquisition, and will play a positive role in further expanding the company’s international business. https://finance.eastmoney.com/a/202608113837991159.html
- Source: drugdu
- 146
- August 12, 2026
Subsidiary’s 9-valent HPV vaccine receives marketing authorization in Thailand

Shanghai Securities News, China Securities Network, August 11 – Wantai Biopharmaceutical…Disclosure regarding the company’s nine-valent HPV vaccineAnnouncement of Marketing Authorization in Thailand. The announcement states that the nine-valent human papillomavirus vaccine (Escherichia coli) independently developed by the company’s wholly-owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has recently received approval from the Thai Food and Drug Administration. The nine-valent HPV vaccine is a preventive biological product independently developed by Wantai Biological Pharmacy Enterprise Co., Ltd.This is my country’s first and the world’s second nine-valent HPV vaccine. It is mainly suitable for women aged 9-45 and covers seven high-risk HPV types (16/18/31/33/45/52/58) and two low-risk HPV types (6/11). It can prevent diseases caused by infection with the above-mentioned human papillomavirus types. The company stated that the approval of the 9-valent HPV vaccine in Thailand marks the first overseas marketing authorization for this product, signifying that it is now qualified for export to ...
- Source: drugdu
- 108
- August 12, 2026
【EXPERT Q&A】Should this inquiry be prioritized for follow-up when the buyer in the pharmaceutical foreign trade scenario starts to request the COA, specification sheet and samples?

Drugdu.com expert’s response: In pharmaceutical foreign trade, after receiving an inquiry, the hardest part is often not figuring out how to reply, but determining which one deserves more of your time investment. Some buyers only send a one-line message saying “Please send price”, while others directly list product specifications, quantities and destination countries. There are also clients who, after two rounds of communication, start requesting COAs, Specifications, GMP documents, and even ask for samples. When several inquiries are laid out in front of you, the one with abundant information may not close a deal immediately, and the seemingly simple inquiry does not necessarily mean there is no procurement plan at all. To judge whether an inquiry is worth following up on with priority, you can refer to several specific behavioral signals from the buyer. Buyers asking about product details are usually more worthy of further exploration than those who only ...
- Source: drugdu
- 72
- August 12, 2026
Medical Philippines

Organiser： Philippine Medical Association, Singapore Fireworks Exhibition Group Time：August 19-21, 2026 Address：Seashell Ln, Pasay, 1300 Metro Manila, Philippines Exhibition hall：SMX Convention Center Manila Product range: Medical Instruments and Equipment: Nursing assistive devices, diagnostic equipment, monitoring equipment, therapeutic equipment, laboratory analysis equipment, surgical specialized equipment, disinfection and sterilization equipment, traction and correction devices, rehabilitation physiotherapy equipment, medical vehicles, beds and tables, first aid and ambulance equipment, surgical devices, diagnostic equipment and supplies, analysis and control instruments, monitoring systems, surgical facilities, preventive medicine equipment, ophthalmic instruments and devices, otolaryngology equipment, dental supplies and equipment, radiological medical equipment, medical reagents and devices, prosthetics and rehabilitation aids, medical health products and supplies, etc. Medical Institution and Laboratory Technical Equipment: Laboratory instruments and equipment, laboratory furniture, laboratory automation and accessories, optical instrument equipment, medical experimental analysis and diagnostic instruments, biopharmaceutical instruments, cell biology instruments, biotechnology equipment, etc. Medical Materials: Artificial organs and implants, dressings ...
- Source: drugdu
- 73
- August 11, 2026
A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap

Recently, Jichuan Pharmaceutical’s independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children’s constipation , enriches the company’s product portfolio, and enhances its core competitiveness in the pediatric field. 01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children’s Medical Center, Capital Medical University), and clinical trials have verified ...
- Source: drugdu
- 69
- August 10, 2026
Vonoprazan Fumarate Tablets Receive Drug Registration Certificate

On August 7th, Huahai Pharmaceutical(600521) issued an announcement stating that the company recently received the “Drug Registration Certificate” for vonoprazan fumarate tablets issued by the National Medical Products Administration. The drug is a tablet, with specifications of 20mg and 10mg, and is registered as a Class 4 chemical drug. Vonoprazan fumarate tablets are used for reflux esophagitis and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Menet.com, the domestic market sales of this drug are projected to reach approximately RMB 282 million in the first quarter of 2026. The company’s R&D investment in the vonoprazan fumarate tablets project is approximately RMB 4.22 million. In the first quarter of 2026, Huahai Pharmaceutical achieved revenue of 2.335 billion yuan and net profit attributable to the parent company of 404 million yuan. https://finance.eastmoney.com/a/202608073835322537.html
- Source: drugdu
- 67
- August 10, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.